Last reviewed · How we verify

Amir Moradi MD, MBA — Portfolio Competitive Intelligence Brief

Amir Moradi MD, MBA pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
OnabotulinumtoxinA 50 UNT [Botox Cosmetic] OnabotulinumtoxinA 50 UNT [Botox Cosmetic] marketed Botulinum toxin SNARE complex (synaptosome-associated protein) Aesthetics / Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Allergan · 1 shared drug class
  3. Beth Israel Deaconess Medical Center · 1 shared drug class
  4. Daewoong Pharmaceutical Co. LTD. · 1 shared drug class
  5. EuBiologics Co.,Ltd · 1 shared drug class
  6. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 shared drug class
  7. Galderma R&D · 1 shared drug class
  8. ASIS Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Amir Moradi MD, MBA:

Cite this brief

Drug Landscape (2026). Amir Moradi MD, MBA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amir-moradi-md-mba. Accessed 2026-05-17.

Related